Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
ABBV-CLS-484 + PD-1/VEGFR Inhibitors for Cancer
Recruiting1 awardPhase 1
Tucson, Arizona
This trial is studying the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) in participants with advanced solid tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service